The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots,聽apixaban is safer than rivaroxaban, with fewer bleeding complications.
The COBRRA trial, led by researchers at The Ottawa Hospital, aimed to directly compare bleeding with apixaban and rivaroxaban in venous thrombosis patients. The trial enrolled 2,760 participants from 32 sites across Canada, Australia and Ireland.
Published in聽, the study was聽senior authored by our Department Chair,聽Dr. Marc Rodger, Physician-in-Chief at the 海角社区 Health Centre, Senior Scientist at the Research Institute of the MUHC, Affiliate Senior Scientist at The Ottawa Hospital and Professor of Medicine at 海角社区.